Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer
Background: The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response.Patients and methods:This single institution...
| Asıl Yazarlar: | , , , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Journal article |
| Dil: | English |
| Baskı/Yayın Bilgisi: |
2013
|
| _version_ | 1826280784812572672 |
|---|---|
| author | Allevi, G Strina, C Andreis, D Zanoni, V Bazzola, L Bonardi, S Foroni, C Milani, M Cappelletti, MR Gussago, F Aguggini, S Giardini, R Martinotti, M Fox, S Harris, A Bottini, A Berruti, A Generali, D |
| author_facet | Allevi, G Strina, C Andreis, D Zanoni, V Bazzola, L Bonardi, S Foroni, C Milani, M Cappelletti, MR Gussago, F Aguggini, S Giardini, R Martinotti, M Fox, S Harris, A Bottini, A Berruti, A Generali, D |
| author_sort | Allevi, G |
| collection | OXFORD |
| description | Background: The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response.Patients and methods:This single institution study comprised 120 oestrogen receptor (ER)-positive postmenopausal women with primary breast cancer (clinical stage ≥T2, N0-1), from three sequential cohorts (cohort A of 40, cohort B of 40 and cohort C of 40 patients, respectively) based on different duration of the neoadjuvant letrozole. Biological markers such as ER, progesterone receptor, HER2 and Ki-67 expression were tested at diagnosis and at definitive surgery.Results:A total of 89 patients (75.4%) achieved an objective response with 44 (37.3%) clinical CRs and 45 (38.1%) partial responses. The clinical CRs were significantly observed in cohort C (23 out of 40 patients, 57.5%) and B (16 out of 38 patients, 42.1%) compared with cohort A (5 out of 40 patients, 12.5%) (P-value for trend <0.001). Letrozole induced a similar significant reduction in Ki-67 index after treatment in all cohorts. The pathCR rate was significantly more frequent in cohort C (7 out of 40 patients, 17.5%) than in cohort A (1 out of 40 patients, 2.5%) and B (2 out of 40 patients, 5.0%) (P-value for trend <0.04).Conclusion:One-year neoadjuvant letrozole therapy leads to a higher pathCR rate and may be the optimal length of drug exposure. © 2013 Cancer Research UK. All rights reserved. |
| first_indexed | 2024-03-07T00:18:55Z |
| format | Journal article |
| id | oxford-uuid:7bd54f6e-6e1f-4450-b833-72c7b5f55b6c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T00:18:55Z |
| publishDate | 2013 |
| record_format | dspace |
| spelling | oxford-uuid:7bd54f6e-6e1f-4450-b833-72c7b5f55b6c2022-03-26T20:53:15ZIncreased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancerJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:7bd54f6e-6e1f-4450-b833-72c7b5f55b6cEnglishSymplectic Elements at Oxford2013Allevi, GStrina, CAndreis, DZanoni, VBazzola, LBonardi, SForoni, CMilani, MCappelletti, MRGussago, FAguggini, SGiardini, RMartinotti, MFox, SHarris, ABottini, ABerruti, AGenerali, DBackground: The objective of this study was to determine the optimal scheduling of 2.5 mg daily letrozole in neoadjuvant breast cancer patients to obtain pathological complete response (pathCR) and assess Ki-67 expression as an early predictor of response.Patients and methods:This single institution study comprised 120 oestrogen receptor (ER)-positive postmenopausal women with primary breast cancer (clinical stage ≥T2, N0-1), from three sequential cohorts (cohort A of 40, cohort B of 40 and cohort C of 40 patients, respectively) based on different duration of the neoadjuvant letrozole. Biological markers such as ER, progesterone receptor, HER2 and Ki-67 expression were tested at diagnosis and at definitive surgery.Results:A total of 89 patients (75.4%) achieved an objective response with 44 (37.3%) clinical CRs and 45 (38.1%) partial responses. The clinical CRs were significantly observed in cohort C (23 out of 40 patients, 57.5%) and B (16 out of 38 patients, 42.1%) compared with cohort A (5 out of 40 patients, 12.5%) (P-value for trend <0.001). Letrozole induced a similar significant reduction in Ki-67 index after treatment in all cohorts. The pathCR rate was significantly more frequent in cohort C (7 out of 40 patients, 17.5%) than in cohort A (1 out of 40 patients, 2.5%) and B (2 out of 40 patients, 5.0%) (P-value for trend <0.04).Conclusion:One-year neoadjuvant letrozole therapy leads to a higher pathCR rate and may be the optimal length of drug exposure. © 2013 Cancer Research UK. All rights reserved. |
| spellingShingle | Allevi, G Strina, C Andreis, D Zanoni, V Bazzola, L Bonardi, S Foroni, C Milani, M Cappelletti, MR Gussago, F Aguggini, S Giardini, R Martinotti, M Fox, S Harris, A Bottini, A Berruti, A Generali, D Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer |
| title | Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer |
| title_full | Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer |
| title_fullStr | Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer |
| title_full_unstemmed | Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer |
| title_short | Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer |
| title_sort | increased pathological complete response rate after a long term neoadjuvant letrozole treatment in postmenopausal oestrogen and or progesterone receptor positive breast cancer |
| work_keys_str_mv | AT allevig increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT strinac increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT andreisd increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT zanoniv increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT bazzolal increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT bonardis increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT foronic increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT milanim increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT cappellettimr increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT gussagof increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT agugginis increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT giardinir increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT martinottim increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT foxs increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT harrisa increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT bottinia increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT berrutia increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer AT generalid increasedpathologicalcompleteresponserateafteralongtermneoadjuvantletrozoletreatmentinpostmenopausaloestrogenandorprogesteronereceptorpositivebreastcancer |